DNA Oyj provided earnings guidance for the year 2018. For the year, net sales and comparable operating result are expected to improve somewhat in 2018 compared with 2017. The company's financial position and liquidity are expected to remain at a healthy level compared with previous guidance of both its net sales and comparable operating result in 2018 to remain at the same level as in 2017. DNA's financial position and liquidity are expected to remain at a healthy level.